Martin Christian Bucher MD , Daniel Andreas Bossard MD , Marco Bonani PD, MD , Michael Paul PhD , Christopher Geinitz PhD , Jérôme Bonzon MD
{"title":"Carboplatin Therapeutic Drug Monitoring in Intermittent Hemodialysis—A Case Report and Review of the Literature","authors":"Martin Christian Bucher MD , Daniel Andreas Bossard MD , Marco Bonani PD, MD , Michael Paul PhD , Christopher Geinitz PhD , Jérôme Bonzon MD","doi":"10.1016/j.clinthera.2025.02.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>We present the case of a 45-year-old female patient with hemodialysis-dependent renal failure due to FSGS who was diagnosed with FIGO IIIc ovarian cancer and treated with carboplatin/gemcitabine under hemodialysis.</div></div><div><h3>Methods</h3><div>A carboplatin dose of 200 mg/m<sup>2</sup> was administered (target AUC 4.0 min*mg/mL). Hemodialysis was started 2 hours after carboplatin administration and continued over 4 hours, with an additional dialysis session the day after.</div></div><div><h3>Findings</h3><div>The measured AUC was 5.8 min*mg/mL.</div></div><div><h3>Implications</h3><div>A dose reduction to 250 mg resulted in an AUC of 2.3 min*mg/mL. This is the first case of an ovarian cancer treated with a high-dose scheme of carboplatin under hemodialysis.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 6","pages":"Pages 450-455"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000694","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
We present the case of a 45-year-old female patient with hemodialysis-dependent renal failure due to FSGS who was diagnosed with FIGO IIIc ovarian cancer and treated with carboplatin/gemcitabine under hemodialysis.
Methods
A carboplatin dose of 200 mg/m2 was administered (target AUC 4.0 min*mg/mL). Hemodialysis was started 2 hours after carboplatin administration and continued over 4 hours, with an additional dialysis session the day after.
Findings
The measured AUC was 5.8 min*mg/mL.
Implications
A dose reduction to 250 mg resulted in an AUC of 2.3 min*mg/mL. This is the first case of an ovarian cancer treated with a high-dose scheme of carboplatin under hemodialysis.
期刊介绍：
Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
